XML 57 R39.htm IDEA: XBRL DOCUMENT v3.22.0.1
Collaboration Agreements And Business Development Activities - Ipsen Collaboration Narrative (Details)
$ in Millions, $ in Millions
12 Months Ended
Dec. 31, 2021
USD ($)
Jan. 01, 2021
USD ($)
Jan. 03, 2020
USD ($)
Dec. 31, 2016
USD ($)
Dec. 31, 2021
CAD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Milestone payments earned to date $ 462.5        
Remaining performance obligation $ 87.5        
Collaboration agreement percent of royalty on net sale 3.00%        
Collaborative arrangement with Ipsen          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Collaboration period to achieve specified levels of commercial performance 10 years        
Upfront payments       $ 210.0  
Milestone payments earned $ 112.5 $ 20.0 $ 55.0    
Eligible payment from collaboration for development and regulatory milestone achievement under collaborations agreement 46.5        
Maximum amount eligible for commercial milestones under collaborations agreement 350.0       $ 26.5
Remaining performance obligation $ 44.2        
Research and development arrangement performed for others, reimbursement for costs incurred, percent 35.00%        
Commercial sales milestone $ 100.0        
Commercial sales milestone, net sales threshold 400.0        
Regulatory milestone 12.5        
Collaborative arrangement with Ipsen | Collaboration services revenues          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Cumulative catch-up revenue recognized $ 43.2        
Collaborative arrangement with Ipsen | Minimum | Final tier          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Percent of royalty on net sale 22.00%        
Collaborative arrangement with Ipsen | Maximum | Final tier          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Percent of royalty on net sale 26.00%